Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Insilico Medicine lands up to $888M deal with French firm Servier to develop cancer drugs using its AI platform.
Insilico Medicine has secured an up to $888 million deal with French drugmaker Servier to develop cancer treatments using its AI platform, Pharma.AI, just days after its Hong Kong IPO.
The agreement includes $32 million in upfront and near-term payments, with additional funds based on milestones.
Insilico will use generative AI to design new drug molecules, while Servier handles R&D, clinical testing, and commercialization.
The company claims its AI can cut drug development time from 4.5 years to 12–18 months.
This deal adds to Insilico’s growing list of AI partnerships, including with Eli Lilly, Fosun Pharma, and Sanofi, with 61 collaborations reported in early 2025.
Despite a slight dip in Insilico’s Hong Kong shares, the healthcare sector there saw increased listings due to supportive policies.
Insilico Medicine llega a un acuerdo de hasta 888 millones de dólares con la firma francesa Servier para desarrollar medicamentos contra el cáncer utilizando su plataforma de IA.